Nokota Management LP Sells 126,750 Shares of Allergan plc (AGN)

Nokota Management LP trimmed its holdings in shares of Allergan plc (NYSE:AGN) by 35.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 232,581 shares of the company’s stock after selling 126,750 shares during the period. Allergan comprises 0.7% of Nokota Management LP’s investment portfolio, making the stock its 29th largest position. Nokota Management LP owned 0.07% of Allergan worth $44,302,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Acadian Asset Management LLC lifted its stake in shares of Allergan by 4,197.7% in the 2nd quarter. Acadian Asset Management LLC now owns 9,154 shares of the company’s stock valued at $1,527,000 after acquiring an additional 8,941 shares during the last quarter. Dupont Capital Management Corp increased its holdings in Allergan by 65.4% during the 2nd quarter. Dupont Capital Management Corp now owns 3,759 shares of the company’s stock valued at $627,000 after purchasing an additional 1,487 shares during the period. Raymond James Financial Services Advisors Inc. increased its holdings in Allergan by 13.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 35,229 shares of the company’s stock valued at $5,874,000 after purchasing an additional 4,275 shares during the period. Commonwealth Equity Services LLC increased its holdings in Allergan by 11.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 54,876 shares of the company’s stock valued at $9,149,000 after purchasing an additional 5,572 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. increased its holdings in Allergan by 2,800.7% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 71,908 shares of the company’s stock valued at $11,989,000 after purchasing an additional 69,429 shares during the period. 78.24% of the stock is currently owned by hedge funds and other institutional investors.

AGN stock opened at $158.09 on Tuesday. Allergan plc has a fifty-two week low of $142.81 and a fifty-two week high of $197.00. The company has a current ratio of 0.92, a quick ratio of 0.78 and a debt-to-equity ratio of 0.32. The company has a market cap of $52.82 billion, a price-to-earnings ratio of 9.67, a PEG ratio of 1.22 and a beta of 1.29.

Allergan (NYSE:AGN) last posted its earnings results on Tuesday, October 30th. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.21. Allergan had a return on equity of 8.44% and a net margin of 14.50%. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.89 billion. During the same quarter in the prior year, the business earned $4.15 EPS. The business’s revenue for the quarter was down 3.0% on a year-over-year basis. On average, analysts expect that Allergan plc will post 16.51 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, December 14th. Shareholders of record on Tuesday, November 13th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, November 9th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.82%. Allergan’s dividend payout ratio (DPR) is 17.61%.

A number of research analysts recently issued reports on the company. Royal Bank of Canada set a $220.00 price target on Allergan and gave the company a “buy” rating in a report on Friday. ValuEngine downgraded Allergan from a “sell” rating to a “strong sell” rating in a report on Friday, November 16th. Leerink Swann assumed coverage on Allergan in a report on Monday, November 12th. They set an “outperform” rating and a $220.00 price target on the stock. Wells Fargo & Co restated a “buy” rating on shares of Allergan in a report on Wednesday, October 31st. Finally, Raymond James reduced their price target on Allergan from $232.00 to $198.00 and set a “buy” rating on the stock in a report on Wednesday, October 31st. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have assigned a buy rating to the stock. Allergan presently has a consensus rating of “Buy” and a consensus price target of $209.18.

In other news, CFO Matthew M. Walsh bought 1,000 shares of Allergan stock in a transaction on Friday, November 16th. The shares were purchased at an average price of $157.00 per share, for a total transaction of $157,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher J. Coughlin purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 6th. The stock was bought at an average price of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. 0.37% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY NOTICE: This article was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2018/12/04/nokota-management-lp-sells-126750-shares-of-allergan-plc-agn.html.

Allergan Profile

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.

Featured Story: Index Funds

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit